Ip Margot M, McGee Sibel O, Masso-Welch Patricia A, Ip Clement, Meng Xiaojing, Ou Lihui, Shoemaker Suzanne F
Department of Pharmacology and Therapeutics and Department of Chemoprevention, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Carcinogenesis. 2007 Jun;28(6):1269-76. doi: 10.1093/carcin/bgm018. Epub 2007 Jan 27.
Conjugated linoleic acid (CLA), a family of isomers of octadecadienoic acid, inhibits rat mammary carcinogenesis, angiogenesis, and lung metastasis from a transplantable mammary tumor. c9,t11-CLA, the predominant isomer in dairy products, and t10,c12-CLA, a component of CLA supplements, are equally effective. The objective of the current studies was to test the efficacy of these two CLA isomers in a clinically relevant breast cancer model. Transgenic mice over-expressing erbB2 in the mammary epithelium were fed control or 0.5% CLA-supplemented diets continuously from weaning. Unexpectedly, t10,c12-CLA stimulated lobular hyperplasia of the mammary epithelium and accelerated mammary tumor development, decreasing median tumor latency to 168 days of age compared with 256 and 270 days in the c9,t11-CLA and control groups, respectively. Metastasis was also increased by t10,c12-CLA, with percentage of tumor-bearing mice with lung metastasis 73, 14 and 31% in the t10,c12-CLA, c9,t11-CLA and control groups, respectively. A second study, in which CLA administration was initiated after puberty, confirmed the stimulatory effect of t10,c12-CLA on mammary tumor development and metastasis. Additionally, t10,c12-CLA, but not c9,t11-CLA, increased the size of the liver, heart, spleen and mammary lymph node. The effects of t10,c12-CLA were not specific to erbB2 transgenic mice, as t10,c12-CLA supplementation increased proliferation in the mammary epithelium of both wild-type FVB and FVB/erbB2 mice. Moreover, the number of terminal end buds, the mammary epithelial structures most sensitive to a carcinogenic insult, was increased 30-fold in FVB wild-type mice fed t10,c12-CLA. These data suggest that it would be prudent to avoid CLA supplements containing the t10,c12-CLA isomer. However, even though c9,t11-CLA was not efficacious in the erbB2 model, its ability to inhibit mammary tumor development in rat models suggests that it may have activity for prevention of some types of breast cancer.
共轭亚油酸(CLA)是十八碳二烯酸的异构体家族,可抑制大鼠的乳腺癌发生、血管生成以及可移植性乳腺肿瘤的肺转移。c9,t11-CLA是乳制品中的主要异构体,而t10,c12-CLA是CLA补充剂的一种成分,二者效果相当。当前研究的目的是在临床相关的乳腺癌模型中测试这两种CLA异构体的功效。从断奶开始,给在乳腺上皮中过表达erbB2的转基因小鼠持续喂食对照饮食或添加0.5%CLA的饮食。出乎意料的是,t10,c12-CLA刺激了乳腺上皮的小叶增生并加速了乳腺肿瘤的发展,与c9,t11-CLA组和对照组分别为256天和270天的中位肿瘤潜伏期相比,t10,c12-CLA组的中位肿瘤潜伏期缩短至168天。t10,c12-CLA还增加了转移,t10,c12-CLA组、c9,t11-CLA组和对照组发生肺转移的荷瘤小鼠百分比分别为73%、14%和31%。第二项研究在青春期后开始给予CLA,证实了t10,c12-CLA对乳腺肿瘤发展和转移的促进作用。此外,t10,c12-CLA增加了肝脏、心脏、脾脏和乳腺淋巴结的大小,但c9,t11-CLA没有。t10,c12-CLA的作用并非erbB2转基因小鼠所特有,因为补充t10,c12-CLA增加了野生型FVB和FVB/erbB2小鼠乳腺上皮的增殖。此外,在喂食t10,c12-CLA的FVB野生型小鼠中,对致癌损伤最敏感的乳腺上皮结构——终末芽的数量增加了30倍。这些数据表明,谨慎起见应避免使用含有t10,c12-CLA异构体的CLA补充剂。然而,尽管c9,t11-CLA在erbB2模型中无效,但其在大鼠模型中抑制乳腺肿瘤发展的能力表明它可能对预防某些类型的乳腺癌有作用。